Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study confirmed that an injectable implant known as RISUG-PH™, when administered via the vas deferens, successfully delivers the drug Finasteride to the prostate in male rats for up to 28 days, suggesting a potential localized alternative to oral delivery methods.

This study identified the N-(iodopropenyl) derivative 13 as a promising candidate for development as a radioiodinated androgen receptor ligand due to its binding affinity.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

The document concludes that using gadolinium-based contrast agents during MRI can be linked to Nephrogenic Systemic Fibrosis in patients with severe kidney disease.

In this study, researchers developed a new prostate cancer imaging agent, a [99m Tc]tricarbonyl complex derived from finasteride, which demonstrated high radiochemical purity and significant uptake in the prostate of a rat model, suggesting its potential for noninvasive prostate cancer imaging.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

This study observed early cardiac effects in young minipigs following high-dose doxorubicin chemotherapy, with a decrease in heart function and changes in cardiac MRI measurements compared to controls.

This study developed dissolving microneedles using specific polymers for transdermal delivery of rizatriptan benzoate, demonstrating improved drug skin penetration and significant alleviation of migraine symptoms in vivo compared to passive diffusion, suggesting potential advantages over conventional treatment methods for acute migraine.

This study found that Dex-loaded hyaluronic acid hydrogel microneedles significantly reduced pain in an acute inflammatory visceral pain model without sedation, suggesting a promising and patient-friendly alternative to intravenous delivery.

This study found that in rodent models, the ability of D1 dopamine receptor activation to impair sensory gating is facilitated by 5α-reductase type 1, which produces allopregnanolone.

Modified HDL can better deliver drugs and genes, potentially improving treatments and reducing side effects.

This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.

In this study, researchers addressed the limitations of adenosine's practical application in treating inflammation, oxidative stress, and tissue repair due to its poor water solubility and low transdermal permeability. Results are not reported in the abstract.

This study found that albumin-bound paclitaxel combined with nedaplatin shows promise as neoadjuvant therapy for esophageal squamous cell carcinoma, achieving a high complete response rate with manageable side effects.

RADA16-I can effectively deliver and release mangiferin, improving its solubility and bioavailability.

In this pilot study, no significant differences were observed between memantine and placebo groups in young adults with Down syndrome on the primary memory outcomes, but some improvement was noted in a secondary measure.

Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.

This study developed a novel smart deoxyribozyme-based fluorescent sensor that efficiently detects androgen receptor mRNA with high selectivity and can be adapted to target various nucleic acid sequences.

This study reported that the combined use of dexmedetomidine and ketamine, along with peripheral nerve blocks, provided adequate sedation and analgesia with maintained hemodynamic stability in patients undergoing minor surgical procedures like split skin grafting.

This meta-analysis reports that trastuzumab deruxtecan is effective and has an acceptable safety profile for treating HER2-low or positive advanced breast cancer, although further research is recommended to support individualized treatment strategies.

This study identifies a mechanism where dsRNA activates TLR3 to induce RA production, promoting hair follicle regeneration in mice and suggesting a potential role in human tissue regeneration.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

This study found that a new quercetin-loaded self-nanoemulsifying drug delivery system improved quercetin bioavailability by 149.8% compared to its suspension in rats.

This study identified common and previously unlisted adverse events associated with four anti-CGRP monoclonal antibodies for migraine prevention, highlighting a varied safety profile post-marketing.